-
Mashup Score: 0Celgene Settlement With Actavis Allows Abraxane Generics In 2022 - 2 year(s) ago
Celgene settles Abraxane patent litigation and inter partes review with Teva’s Actavis, allowing a generic to enter the market on March 31, 2022 – about four years before the drug’s key patents expire.
Source: ScripCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Pipeline Watch: 13 Approvals And Five Topline Phase III Readouts - 2 year(s) ago
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
An unexpected miss for AstraZeneca’s checkpoint inhibitor Imfinzi in cervical cancer, in the wake of other rivals dropping out, leaves Merck & Co’s Keytruda more firmly in command of the market.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 3Orphazyme Teeters On The Brink As Arimoclomol File Is Pulled - 2 year(s) ago
All hopes for survival rest on a meeting with the US FDA about arimoclomol now that the Danish biotech has withdrawn its submission for the Niemann-Pick disease type C therapy with the European Medicines Agency.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2Stock Watch: Brace For European Biotech Departures From NASDAQ - 2 year(s) ago
A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer - 2 year(s) ago
Metastatic prostate cancer continues to evade the checkpoint inhibitor class but Merck is not giving up on an area where overall survival remains limited.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Pipeline Watch: 10 Approvals And Seven Phase III Trial Updates - 2 year(s) ago
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
The big pharma has a gene therapy R&D site in New York from its Prevail Therapeutics buy; the RNA-focused Boston site also will conduct drug delivery research benefitting programs at both locations.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Almirall In The Market For Bolt-On Acquisitions - 2 year(s) ago
Much of Almirall’s attention this year will be on submitting the potential atopic dermatitis blockbuster lebrikizumab in Europe but the Spanish firm is also looking at bringing in some other late-stage products.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
@drallysonocean Abraxane is going to go generic soon …. https://t.co/bfG5eBlgIg.